CBD shows promise in curbing opioid cravings

NCT ID NCT03787628

Completed Disease control Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether cannabidiol (CBD) can reduce cravings and prevent relapse in people with opioid use disorder who are already taking standard medications like buprenorphine or methadone. Thirty-five participants received either CBD or a placebo for 28 days while in residential treatment. Researchers tracked side effects, cravings, and drug use through questionnaires and urine tests over a 10-week period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cannabidiol (CBD)
What this could lead to: If it works, CBD could become an add-on treatment to help people with opioid use disorder stay in recovery and avoid relapse.
What could go wrong: This was a small, early-phase study with only 35 participants, so results may not apply broadly. CBD may not reduce craving or prevent relapse better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Tarzana Treatment Centers

Tarzana, California, 91356, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.